MPN Midyear Updates from EHA and ASCO with Dr. Claire Harrison image

MPN Midyear Updates from EHA and ASCO with Dr. Claire Harrison

Jul 08, 2026
12:00PM - 01:00PM EDT
Online Event
Overview

Join the HealthTree Foundation for MPN for this exciting midyear update. The amazing Dr. Claire Harrison will be joining us to share highlights from the American Society of Clinical Oncology and European Hematology Association conferences. This is a great opportunity to hear from one of the world's leading experts in MPNs about the key findings shared at these conferences. Come ready to learn and ready to ask questions!

 

Agenda
12:00 PM
Introductions
Dalton Bean

Dalton introduces the agenda of the event and featured speaker Dr. Claire Harrison

12:05 PM
Presentation
Claire Harrison, MD, FRCP, FRCPath

Dr. Claire Harrison will be joining us to share highlights from the American Society of Clinical Oncology and European Hematology Association conferences.

12:45 PM
Questions & Answers
Audience

Bring your questions!

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Claire Harrison, MD, FRCP, FRCPath

Claire Harrison, MD, FRCP, FRCPath

Professor Claire Harrison graduated from Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy chief medical officer. The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. Her work has led to the approval of new therapies such a ruxolitinib, fedratinib, momelotinib and pacritinib. In the past 10 years she has published widely (>300 academic articles). In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.